Page Banner

United States Department of Agriculture

Agricultural Research Service

Research Project: Understanding Genetic and Physiological Factors Affecting Nutrient Use Efficiency of Dairy Cattle

Location: Animal Genomics and Improvement Laboratory

Title: Glucagon-like peptide 2 therapy reduces the negative impacts the proinflammatory response in the gut of calves with coccidiosis

Authors
item Connor, Erin
item Kahl, Stanislaw
item Elsasser, Theodore
item Baldwin, Ransom
item Fayer, Ronald
item Santin-Duran, Monica
item Sample, Gregory
item Clover, Christina

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: November 6, 2012
Publication Date: November 20, 2012
Citation: Connor, E.E., Kahl, S., Elsasser, T.H., Baldwin, R.L., Fayer, R., Santin, M., Sample, G.L., Clover, C.M. 2012. Glucagon-like peptide 2 therapy reduces the negative impacts the proinflammatory response in the gut of calves with coccidiosis. Meeting Abstract. p.17.Paper No. 403.

Technical Abstract: Damage to the intestinal epithelium reduces nutrient absorption and animal growth, and can have negative long-term health effects on livestock. The intestinotropic hormone glucagon-like peptide 2 (GLP-2) contributes to gut integrity, reduces inflammation, and improves nutrient absorption. The present study was designed to determine whether GLP-2 administration to calves with coccidiosis in the first month of life affects intestinal growth and mediates negative impacts of the proinflammatory response. Holstein bull calves (n = 19) were assigned to 4 treatment groups of 4 to 5 calves each: 1) infected with Eimeria bovis, GLP-2-treated; non-infected, GLP-2-treated; 3) infected with E. bovis, buffer-treated; and 4) non-infected, buffer-treated. On d 0, infected calves received 100,000 to 200,000 sporulated E. bovis oocysts suspended in milk replacer. On d 18, calves in the GLP-2 groups received a subcutaneous injection of 50 µg/kg BW of bovine GLP-2 twice daily for 10 d, and calves in the buffer-treated groups received an equivalent volume of buffer. On d 28, calves were euthanized 2 h after injection of 5-bromo-2'-deoxyuridine (BrdU). Intestinal tissues were measured and villus height, crypt depth, and BrdU immunostaining were evaluated in segments of the small intestine. Nitrotyrosine immunostaining, a measure of nitro-oxidative damage, was evaluated in ileum and cecum. There was a GLP-2 treatment by E. bovis infection interaction only for nitrotyrosine immunostaining in cecum (P = 0.005). Large intestinal weight was greater (P = 0.03) in infected than non-infected calves and with GLP-2 treatment relative to buffer treatment. Calves that received GLP-2 had greater (P = 0.01) small intestinal weight relative to buffer-treated calves, but an increase in cell proliferation was detected only in jejunum (P = 0.08), as assessed by BrdU labeling. No treatment effects were detected (P = 0.12) for villus height, crypt depth, or villus height:crypt depth ratio in segments of the small intestine. Protein tyrosine nitration was over 3-fold greater (P = 0.004) in ileum and cecum of infected calves relative to non-infected calves, and GLP-2 therapy reduced tyrosine nitration in infected calves by 47% in ileum (P < 0.05) and 69% in cecum (P < 0.0001) relative to buffer-treated calves. Thus, GLP-2 promotes intestinal growth in neonatal calves and GLP-2 therapy reduces the detrimental effects of nitro-oxidative stress in ileocecum of calves with coccidiosis.

Last Modified: 10/20/2014
Footer Content Back to Top of Page